Evidence map›Paper›PMID 28917029›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2018

Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma.

S de Groot, W K Redekop, M M Versteegh, S Sleijfer, E Oosterwijk, L A L M Kiemeney, C A Uyl-de Groot

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 3 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Treatments for renal cell carcinoma: NICE Pilot Treatment Pathways Appraisal.Health technology assessment (Winchester, England) · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. A qualitative approach to understanding quality symptom management in routine oncology outpatient care: phase 1 of the symptom pathways project.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

S de GrootErasmus School of Health Policy and Management, Erasmus University Rotterdam, P. O. Box 1738, 3000 DR, Rotterdam, The Netherlands. degroot@imta.eur.nl.
W K RedekopErasmus School of Health Policy and Management, Erasmus University Rotterdam, P. O. Box 1738, 3000 DR, Rotterdam, The Netherlands.
M M VersteeghErasmus School of Health Policy and Management, Erasmus University Rotterdam, P. O. Box 1738, 3000 DR, Rotterdam, The Netherlands.
S SleijferDepartment of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, P. O. Box 5201, 3008 AE, Rotterdam, The Netherlands.
E OosterwijkDepartment of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, P. O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
L A L M KiemeneyDepartment of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, P. O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
C A Uyl-de GrootErasmus School of Health Policy and Management, Erasmus University Rotterdam, P. O. Box 1738, 3000 DR, Rotterdam, The Netherlands.
Erasmus University Rotterdam · NLRadboud Institute for Molecular Life Sciences · NLErasmus MC Cancer Institute · NL

Funding

ZonMw 152001014
6 · The paper itself

Abstract

purposeBased on improvements of progression-free survival (PFS), new agents for metastatic renal cell carcinoma (mRCC) have been approved. It is assumed that one of the benefits is a delay in health-related quality of life (HRQoL) deterioration as a result of a delay in progression of disease. However, little data are available supporting this relationship. This study aims to provide insight into the most important determinants of HRQoL (including progression of disease) of patients with mRCC.

methodsA patient registry (PERCEPTION) was created to evaluate treatment of patients with (m)RCC in the Netherlands. HRQoL was measured, using the EORTC QLQ-C30 and EQ-5D-5L, every 3 months in the first year of participation in the study, and every 6 months in the second year. Participation started as soon as possible following a diagnosis of (m)RCC. Random effects models were used to study associations between HRQoL and patient and disease characteristics, symptoms and treatment.

resultsEighty-seven patients with mRCC completed 304 questionnaires. The average EORTC QLQ-C30 global health status was 69 (SD, 19) before progression and 61 (SD, 22) after progression of disease. Similarly, the average EQ-5D utility was 0.75 (SD, 0.19) before progression and 0.66 (SD, 0.30) after progression of disease. The presence of fatigue, pain, dyspnoea, and the application of radiotherapy were associated with significantly lower EQ-5D utilities.

conclusionsKey drivers for reduced HRQoL in mRCC are disease symptoms. Since symptoms increase with progression of disease, targeted therapies that increase PFS are expected to postpone reductions in HRQoL in mRCC.

Indexed as

Health StatusAdultAgedCarcinoma, Renal CellCost-Benefit AnalysisDisease-Free SurvivalFemaleHumansMaleMiddle AgedNeoplasm MetastasisQuality of LifeSurveys and QuestionnairesCost-effectiveness analysisEORTC QLQ-C30EQ-5DHealth-related quality of lifeMetastatic renal cell carcinomaTargeted therapy

Identifiers

PMID28917029
PMCPMC5770482
OpenAlexW2755525655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.